CAS Number: 942195-55-3
Chemical Formula: C₂₀H₁₉F₂N₃O₃
Indicación terapéutica: Tratamiento de trastornos gastrointestinales relacionados con el ácido mediante bloqueo competitivo del ácido por potasio (P-CAB), posicionado como alternativa a los inhibidores de la bomba de protones (IBP)
IUPAC Name: 7-[[(4S)-5,7-difluoro-3,4-dihydro-2H-chromen-4-yl]oxy]-N,N,2-trimethyl-3H-benzimidazole-5-carboxamide
EC Number:
Molecular Weight: 387.4
Forma farmacéutica: Formulado como comprimidos orales para dosificación una vez al día, conforme a la presentación típica de los P-CAB
Estado de aprobación regulatoria: Desarrollo clínico de fase 3 completado en Corea, con estudios adicionales de fase 3 realizados a nivel internacional

Otra información

Descripción adicional:

Tegoprazan is a novel, patented potassium-competitive acid blocker (P-CAB) that addresses limitations found in traditional proton pump inhibitors (PPIs) and rival P-CABs. Its advantages have been shown through Phase 3 trials in Korea and a Phase 1 trial in the US, leading to MFDS approval in 2019 across four indications: erosive reflux disease (ERD), non-erosive gastroesophageal reflux disease (NERD), gastric ulcer (GU), and Helicobacter pylori eradication. Beyond South Korea, it has gained approval in China, Mongolia, and the Philippines, among the 34 countries where HK inno.N has out-licensed it, and the company is actively seeking partners to develop Tegoprazan in unpartnered territories. Contact Ga-Young Lee (BD) at [email protected] for details.